Result: Risk Minimisation Materials for medicines starting with the letter R

Ranexa

A. Menarini Farmaceutica Internazionale SRL

Remicade

Merck Sharp & Dohme Limited

Remicade (Infliximab): Important Safety Information to reduce the risk of adverse events: Healthcare Professional

The Important safety information contains a summary of the key safety aspects required by Healthcare Professionals who are likely to treat patients with Remicade. This is part of the terms of the Marketing Authorisation. If you require further information about Remicade and hard copies of the material please contact [email protected] If you have any questions or require additional information, please call MSD Medical Information services on 01992 467272.

For Healthcare Professionals

Remicade (Infliximab): Patient Alert Card

The provision of this card to patients is required by the terms of the Marketing Authorisation. Please ensure that you carry this card with you at all times and that you have read and understood this information as it contains important safety information that you need to be aware of before, during and after treatment with Remicade.

Remsima

Napp Pharmaceuticals Limited

Remsima Patient Alert Card

Patient Alert Card

For Healthcare Professionals

Remsima Patient Screening Sheet

Patient Screening Sheet

For Healthcare Professionals

Remsima Safety Sheet

Safety Sheet

For Healthcare Professionals

Rifadin

SANOFI

Rifampicin, Rifadin 100mg/5mL Oral Suspension DHCP letter

Rifampicin, Rifadin 100mg/5mL Oral Suspension – Caution in Use – Unusual consistency in batch A6140

For Healthcare Professionals

Rixathon

Sandoz Limited

Rixathon (rituximab) Patient Educational Leaflet - Important safety information for patients receiving Rixathon therapy

The information provided in this booklet should be discussed with patients by their healthcare professional during Rixathon(rituximab) treatment. This material is provided as a licence requirement for this medicine and forms part of the Risk Management Plan.

Roaccutane

Roche Products Limited

Checklist for Prescribing to Female Patients

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme. This checklist should be completed by the prescriber prior to initiating therapy with Roaccutane

For Healthcare Professionals

Contraception Advice for People Taking Roaccutane

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme. This booklet should only be given to patients who have been prescribed Roaccutane. This booklet discusses the different types of contraception, how to use them and how effective they are

Pharmacist’s Guide to Dispensing Roaccutane

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme. This booklet is intended for pharmacists who are involved with dispensing Roaccutane and it provides a guide to dispensing Roaccutane in accordance with the Pregnancy Prevention Programme

For Healthcare Professionals

Physician’s Guide to Prescribing Roaccutane

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme. This booklet is intended for physicians who prescribe Roaccutane and it provides a summary of the Pregnancy Prevention Programme

For Healthcare Professionals

Roaccutane Patient Information Booklet

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Pregnancy Prevention Programme. This booklet should be given to patients who have been prescribed Roaccutane and it describes some of the important facts about Roaccutane that you need to be aware of

RoActemra

Roche Products Limited

RoActemra (tocilizumab) – Patient Brochure for Giant Cell Arteritis SC Formulation

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

For Healthcare Professionals

RoActemra (tocilizumab) Guide for HCPs – Important Efficacy and Safety Information for RA and GCA

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

For Healthcare Professionals

RoActemra (tocilizumab) Guide for HCPs – Step-by-Step Dosing and Administration Guide – IV and SC for RA and GCA

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

For Healthcare Professionals

RoActemra (tocilizumab) Important Efficacy and Safety Information for HCPs - IV for sJIA and pJIA

This material is provided by Roche Products Ltd as part of the Risk Management Plan

For Healthcare Professionals

RoActemra (tocilizumab) IV Dosing for Polyarticular Idiopathic Arthritis (pJIA)

This material is provided by Roche Products Ltd as part of the Risk Management Plan.

For Healthcare Professionals

RoActemra (tocilizumab) IV Infusion Dosing for Rheumatoid Arthritis (RA)

This material is provided by Roche Products Ltd as part of the Risk Management Plan.

For Healthcare Professionals

RoActemra (tocilizumab) Macrophage Activation Syndrome (MAS) in sJIA

This material is provided by Roche Products Ltd as part of the Risk Management Plan.

For Healthcare Professionals

RoActemra (tocilizumab) Patient Alert Card for Paediatric and Adult Patients

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan.

RoActemra (tocilizumab) Step by Step Dosing and Administration Guide for HCPs - IV for pJIA and sJIA

This material is provided by Roche Products Ltd as part of the Risk Management Plan.

For Healthcare Professionals